On June 17, 2022, the Federal Court of Canada issued its judgment in Benjamin Moore & Co v Attorney General of Canada, 2022 FC 923. The case defines a new test for statutory subject matter under the Patent Act as applied to computer-implemented inventions.
The case was an appeal from a decision of the Patent Appeal Board at the Canadian Intellectual Property Office (CIPO) in which patent eligibility was denied to two patent applications filed by Benjamin Moore & Co The inventions claimed in the two applications relate to computer-implemented systems and methods for selecting colours based on scientific findings associating certain mathematically determined colour values with human psychophysical responses.
The appeal was argued on behalf of Benjamin Moore & Co by a litigation team at Ridout & Maybee LLP, which is now part of Smart & Biggar, consisting of Matt Norwood, Ben Mak, Abbas Kassam, and Erin Stuart. The Intellectual Property Institute of Canada (IPIC) joined the case as a third-party intervener.
Ultimately, the Court adopted the test for statutory subject matter in computer implemented inventions proposed by IPIC and endorsed by Benjamin Moore & Co. The test requires that CIPO evaluate statutory subject matter during examination of computer-implemented inventions by performing three steps:
1. Purposively construe the claim.
2. Ask whether the construed claim as a whole consists of only a mere scientific principle or abstract theorem, or whether it comprises a practical application that employs a scientific principle or abstract theorem.
3. If the construed claim comprises a practical application, assess the construed claim for the remaining patentability criteria: statutory categories and judicial exclusions, as well as novelty, obviousness, and utility.
The Court ordered the two Benjamin Moore & Co patent applications to be sent back to CIPO for a new determination of patentability under the new test.
Related Publications & Articles
-
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More -
New USPTO rules will affect Canadian innovators not represented by a patent attorney or patent agent
Foreign filing licenses are a common but often overlooked requirement that can create headaches for patent applicants. Failure to obtain the appropriate authorization can lead to consequences ranging ...Read More -
Government of Canada launches consultation on expanding the geographical indications regime
On May 28, 2026, the Government of Canada launched a public consultation on the scope of the geographical indications (GIs) regime under the Trademarks Act. The consultation seeks stakeholders' views ...Read More
